Results 11 to 20 of about 24,855,408 (292)

JAK2 (janus kinase 2) [PDF]

Atlas of Genetics and Cytogenetics in Oncology and Haematology, 2010
Review on JAK2 (janus kinase 2), with data on DNA, on the protein encoded, and where the gene is implicated.
Huret, JL
openaire   +4 more sources

Janus kinase inhibitors: jackpot or potluck?

Oncology Reviews, 2012
The reports of a unique mutation in the Janus kinase-2 gene (JAK2) in polycythemia vera by several independent groups in 2005 quickly spurred the development of the Janus kinase inhibitors.
Pavithran Keechilat, Shripad Brahmanand Pande   +1 more
doaj   +2 more sources

Janus kinase 2 inhibition by pacritinib as potential therapeutic target for liver fibrosis. [PDF]

Hepatology, 2023
Diagram of the activation of the profibrotic and procontractile Janus kinase 2 (JAK2)/Ras homolog family member A/Rho‐kinase pathway and the inhibition of phosphorylated JAK2 by pacritinib to inhibit hepatic stellate cell activity. Abstract Background and Aims Janus kinase 2 (JAK2) signaling is increased in human and experimental liver fibrosis with ...
Torres S, Ortiz C, Bachtler N, Gu W, Grünewald LD, Kraus N, Schierwagen R, Hieber C, Meier C, Tyc O, Joseph Brol M, Uschner FE, Nijmeijer B, Welsch C, Berres ML, Garcia-Ruiz C, Fernandez-Checa JC, Trautwein C, Vogl TJ, Zeuzem S, Trebicka J, Klein S.   +21 more
europepmc   +2 more sources

Assay Development and Inhibitor Screening for Janus Kinase 2 [PDF]

, 2023
Janus kinase 2 (JAK2) is an essential mediator of hematopoietic and growth signaling in cells. It signals as a part of the Janus kinase and signal transducer and activator of transcription (JAK-STAT) pathway, which ultimately regulates gene expression by mediating cytokine signaling from a diverse set of cytokines.
Pölläniemi, Angelika
openaire   +2 more sources

A JAK of all trades: how global phosphoproteomics reveal the Achilles heel of MPNs

Molecular & Cellular Oncology, 2021
While Janus-kinase (JAK)-inhibitors effectively reduce the inflammatory phenotype of myeloproliferative neoplasms (MPN), they do not affect disease burden or presence of the mutated clone to a major extent. Here, we show how Janus-kinase 2 (JAK2)-mutated
Tina M. Schnoeder, Florian Perner, Florian H. Heidel   +2 more
doaj   +1 more source

Overexpression of Janus kinase 2 protein in extramammary Paget’s disease [PDF]

Japanese Journal of Clinical Oncology, 2021
Abstract Extramammary Paget’s disease is a rare malignant tumor of the skin that occurs primarily in the genitocrural region. Although the prognosis of extramammary Paget’s disease with distant metastasis is poor, an effective therapy has not been established.
Saki, Otsuka-Maeda, Myangat Tselmeg, Mijiddorj, Ikko, Kajihara, Ryoko, Sakamoto, Saori, Yamada-Kanazawa, Hisashi, Kanemaru, Yuki, Nishimura, Soichiro, Sawamura, Katsunari, Makino, Jun, Aoi, Takamitsu, Makino, Shinichi, Masuguchi, Satoshi, Fukushima, Hironobu, Ihn   +13 more
openaire   +2 more sources

Ruxolitinib suppresses liver fibrosis progression and accelerates fibrosis reversal via selectively targeting Janus kinase 1/2

Journal of Translational Medicine, 2022
Background JAK1 and JAK2 have been implicated in fibrosis and cancer as a fibroblast-related marker; however, their role in liver fibrosis has not been elucidated.
Zhenghui Song, Xinhui Liu, Wan Zhang, Yue Luo, Hua Xiao, Yun Liu, Guanqi Dai, Jian Hong, Aimin Li   +8 more
doaj   +1 more source

In silico method potential therapeutic use of Janus Kinase inhibitors as severe acute respiratory syndrome coronavirus 2 main protease inhibitors

Journal of the Scientific Society, 2023
Background: Coronavirus disease 2019 (COVID-19), it is an infectious respiratory disease caused by SARS corona virus 2 (SARS CoV-2). There are several reports of using JAK (Janus kinase)-inhibitors in persons with COVID-19 and the use of these decreased ...
Shankar Gharge, Sushmita I Hiremath, Akshata S Menasinakai, Mahesh S Palled   +3 more
doaj   +1 more source

Pharmacology of inhibitors of Janus kinases – Part 2: Pharmacodynamics

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, 2022
SummaryAs small molecules, the Janus kinase inhibitors have different, dose‐dependent pharmacological binding selectivities, which, however, do not allow reliable statements about the clinical specificity of desired or side effects. It is therefore of particular importance to recognize that the pharmacodynamics of the individual Janus kinase inhibitors
Adina, Eichner, Johannes, Wohlrab
openaire   +2 more sources

An accurate, simple prognostic model consisting of age, JAK2, CALR, and MPL mutation status for patients with primary myelofibrosis

Haematologica, 2017
In most patients with primary myelofibrosis, one of three mutually exclusive somatic mutations is detected. In approximately 60% of patients, the Janus kinase 2 gene is mutated, in 20%, the calreticulin gene is mutated, and in 5%, the myeloproliferative ...
Uri Rozovski, Srdan Verstovsek, Taghi Manshouri, Vilma Dembitz, Ksenija Bozinovic, Kate Newberry, Ying Zhang, Joseph E. Bove, Sherry Pierce, Hagop Kantarjian, Zeev Estrov   +10 more
doaj   +1 more source